During the last session, Spero Therapeutics Inc (NASDAQ:SPRO)’s traded shares were 4.48 million, with the beta value of the company hitting 0.55. At the end of the trading day, the stock’s price was $1.74, reflecting an intraday gain of 4.82% or $0.08. The 52-week high for the SPRO share is $2.00, that puts it down -14.94 from that peak though still a striking 43.1% gain since the share price plummeted to a 52-week low of $0.99. The company’s market capitalization is $92.22M, and the average intraday trading volume over the past 10 days was 0.66 million shares, and the average trade volume was 216.94K shares over the past three months.
Spero Therapeutics Inc (NASDAQ:SPRO) trade information
Spero Therapeutics Inc (SPRO) registered a 4.82% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 4.82% in intraday trading to $1.74, hitting a weekly high. The stock’s 5-day price performance is 0.58%, and it has moved by 19.18% in 30 days. Based on these gigs, the overall price performance for the year is 17.57%. The short interest in Spero Therapeutics Inc (NASDAQ:SPRO) is 0.56 million shares and it means that shorts have 2.51 day(s) to cover.
Spero Therapeutics Inc (SPRO) estimates and forecasts
Statistics show that Spero Therapeutics Inc has underperformed its competitors in share price, compared to the industry in which it operates. Spero Therapeutics Inc (SPRO) shares have gone up 34.88% during the last six months, with a year-to-date growth rate less than the industry average at -313.95% against 13.40. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -118.20% this quarter and then jump 16.00% in the quarter after that.
Meanwhile, a consensus of 3 analyst(s) estimates revenue growth to $13 million by the end of Mar 2024. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $47.44 million and $1 million respectively.
While earnings are projected to return -274.42% in 2024, the next five years will return 36.90% per annum.
SPRO Dividends
Spero Therapeutics Inc is due to release its next quarterly earnings between May 09 and May 13. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Spero Therapeutics Inc (NASDAQ:SPRO)’s Major holders
Spero Therapeutics Inc insiders own 20.69% of total outstanding shares while institutional holders control 26.50%, with the float percentage being 33.42%. Anson Funds Management LP is the largest shareholder of the company, while 59 institutions own stock in it. As of Jun 29, 2023, the company held over 3.44 million shares (or 6.53% of all shares), a total value of $5.0 million in shares.
The next largest institutional holding, with 1.53 million shares, is of Vanguard Group Inc’s that is approximately 2.90% of outstanding shares. At the market price on Jun 29, 2023, these shares were valued at $2.21 million.
Also, the Mutual Funds coming in first place with the largest holdings of Spero Therapeutics Inc (SPRO) shares are Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. Data provided on Jun 29, 2023 indicates that Vanguard Total Stock Market Index Fund owns about 0.9 million shares. This amounts to just over 1.70 percent of the company’s overall shares, with a $1.3 million market value. The same data shows that the other fund manager holds slightly less at 0.58 million, or about 1.10% of the stock, which is worth about $0.84 million.
